Loading organizations...
Shepherd Ventures operates as a venture capital fund, committed to generating significant capital appreciation through investments in growth-stage companies. The firm primarily targets opportunities within the information technology and life sciences sectors, providing a hands-on approach by offering extensive operating experience, advisory networks, and strategic partnerships to support its portfolio. This active involvement is central to their strategy for fostering success in selected enterprises.
The fund was co-founded by George C. Kenney, who also serves as a Managing Director. The team comprises seasoned venture capitalists, entrepreneurs, and senior operating executives, whose collective experience informs their investment thesis. An insight driving the firm's establishment and continued focus is the perceived competitive advantage within Southern California’s Tech Coast, a region with robust technology and life science industries yet historically underserved by venture capital.
Shepherd Ventures seeks investment candidates characterized by strong leadership, compelling value propositions, and substantial upside potential. The firm’s vision centers on leveraging its local presence and the team's extensive networks to identify and support promising companies within its focused geographic and industry sectors. This strategic localization underpins their approach to discovering and nurturing high-growth opportunities.
Shepherd Ventures has 4 tracked investments across 1 company. The latest tracked deal is $104.0M Other Equity / Series E in Revance Therapeutics in April 2013.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 2, 2013 | Revance Therapeutics | $104.0M Other Equity / Series E | — | Bio*one Capital, Delphi Ventures, Novaquest Capital Management, PAC Link Ventures, Palo Alto Investors, Technology Partners, Vivo Ventures |
| Jun 10, 2011 | Revance Therapeutics | $45.0M Other Equity | Jonathan Tunnicliffe | CNF Investments, Essex Capital Corporation, PAC Link Ventures, Palo Alto Investors, Technology Partners, Vivo Ventures |
| Jun 1, 2011 | Revance Therapeutics | $45.0M Series D | Essex Woodlands, Novaquest Capital Management | Vivo Capital, CNF Investments, Essex Capital Corporation, PAC Link Ventures, Palo Alto Investors, Technology Partners |
| Jan 1, 2010 | Revance Therapeutics | $26.0M Series D | — | Vivo Capital, Bio*one Capital, PAC Link Ventures, Palo Alto Investors, Technology Partners, Vivo Ventures |